Stocktoria
Mineralys Therapeutics, Inc. MLYS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2023-02-10
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Operating income | -$170.6M | -$192.4M | -$84.7M | -$31.5M |
| Net income | -$154.7M | -$177.8M | -$71.9M | -$29.8M |
| Operating cash flow | -$142.4M | -$166.3M | -$81.2M | -$29.2M |
| Total assets | $661.8M | $205.9M | $251.6M | $114.4M |
| Shareholders' equity | $646.7M | $191.3M | $241.2M | -$52.3M |
| Ratios | ||||
| Return on assets | -23.4% | -86.4% | -28.6% | -26.0% |
| Return on equity | -23.9% | -93.0% | -29.8% | 57.0% |
| Current ratio | 43.76 | 14.02 | 23.76 | 13.98 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 1,911,433 | $51.8M |
| RENAISSANCE TECHNOLOGIES LLC | 382,800 | $10.4M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001933414 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.